EirGenix Inc. (TPE:6589)

Market Cap	21.14B
Revenue (ttm)	955.40M
Net Income (ttm)	-901.57M
Shares Out	302.37M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,735,589
Average Volume	1,093,532
Open	61.00
Previous Close	60.80
Day's Range	60.00 - 61.50
52-Week Range	52.70 - 96.10
Beta	0.45
RSI	76.60
Earnings Date	Nov 12, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 207
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6589

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.